Drug recall · December 18, 2024
Levothyroxine Sodium Tablets USP recall
Why: Superpotent Drug and Subpotent Drug: potency failures obtained
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Levothyroxine Sodium Tablets USP, 200 mcg, packaged in a) 90-count bottles (NDC 0378-1819-77) and b) 1000-count bottles (NDC 0378-1819-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.
- Lots / codes
Lot #: a)8179847, Exp. Date July 2025; b) 3203518, Exp. Date July 2025
- Quantity
- 55,032 bottles
- Company
- Viatris Inc, Canonsburg, PA
- Distribution
- Nationwide within the United States and Puerto Rico
- Initiated
- November 18, 2024 · Voluntary: Firm initiated
- Classified
- December 12, 2024
- Reported
- December 18, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Levothyroxine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.